Key Takeaways
- • Isomorphic Labs closed a $2.1B Series B funding round led by Thrive Capital, bringing total external capital raised to $2.7B since spinning out of Alphabet in 2021.
- • The funding syndicate includes Alphabet, GV, CapitalG, MGX (Abu Dhabi sovereign wealth fund), Temasek (Singapore sovereign wealth fund), and the U.K. government's AI fund, signaling strong institutional confidence in AI-driven drug discovery.
- • Isomorphic's core technology, IsoDDE (Isomorphic Drug Design Engine), leverages AlphaFold 3—the protein structure prediction model for which founder Demis Hassabis won the 2024 Nobel Prize in Chemistry—to design drug molecules computationally before laboratory synthesis.
- • Capital will accelerate development of Isomorphic's internal drug candidate pipeline toward clinical trials and scale the IsoDDE platform globally, with the company partnering alongside pharma incumbents including Eli Lilly and Novartis.
- • The round represents one of the largest biotech funding events in 2026, underscoring investor appetite for AI-native approaches to drug discovery that compress development timelines and reduce failure rates.
Summary
Isomorphic Labs, the AI-focused drug discovery company spun out of Alphabet in 2021 and led by DeepMind founder Demis Hassabis, has raised $2.1 billion in Series B funding. The round was led by Thrive Capital, run by investor Josh Kushner, and closed with participation from a heavyweight syndicate spanning strategic corporate investors, sovereign wealth funds, and government-backed technology funds. Beyond lead investor Thrive Capital, the round included Alphabet itself, GV (formerly Google Ventures), CapitalG (Alphabet's growth fund), MGX (a technology-focused investment vehicle backed by Abu Dhabi), Singapore's Temasek sovereign wealth fund, and the U.K. government's AI fund.
The company's proprietary platform, IsoDDE (Isomorphic Drug Design Engine), represents a computational approach to molecular drug design. The system uses artificial intelligence to generate drug molecules from first principles and predict how those molecules will interact with biological targets at the atomic level—eliminating the need for expensive, time-consuming wet lab screening in early discovery phases. The technological foundation rests on AlphaFold 3, Hassabis's breakthrough protein structure prediction model that resolved a 50-year computational biology problem. Hassabis's work on AlphaFold earned him the 2024 Nobel Prize in Chemistry, validating the underlying science that now powers Isomorphic's commercial platform.
This $2.1 billion Series B follows a prior $600 million external funding round, bringing cumulative external capital raised to $2.7 billion. According to company guidance, Hassabis has stated that the funding supports Isomorphic's ambition to build a scalable drug design engine capable of addressing diseases across multiple therapeutic domains. The capital will be deployed to refine and expand the IsoDDE platform, scale global operations, and advance Isomorphic's internal drug development pipeline toward clinical trial entry. The company is simultaneously working with established pharmaceutical partners including Eli Lilly and Novartis, indicating both internal development and partnership-based commercialization strategies.
The funding composition—heavily weighted toward Alphabet-affiliated entities alongside tier-one sovereign wealth funds and government backing—reflects institutional recognition that AI-driven drug discovery has matured beyond speculative territory. The participation of Temasek and MGX, alongside the U.K. sovereign AI fund, signals geopolitical competition for AI biotech leadership. For institutional investors, the round signals Alphabet's deepening commitment to biotech as a core growth vector and validates the venture-scale capital requirements now needed to compete in AI-native therapeutics discovery.
The company's proprietary platform, IsoDDE (Isomorphic Drug Design Engine), represents a computational approach to molecular drug design. The system uses artificial intelligence to generate drug molecules from first principles and predict how those molecules will interact with biological targets at the atomic level—eliminating the need for expensive, time-consuming wet lab screening in early discovery phases. The technological foundation rests on AlphaFold 3, Hassabis's breakthrough protein structure prediction model that resolved a 50-year computational biology problem. Hassabis's work on AlphaFold earned him the 2024 Nobel Prize in Chemistry, validating the underlying science that now powers Isomorphic's commercial platform.
This $2.1 billion Series B follows a prior $600 million external funding round, bringing cumulative external capital raised to $2.7 billion. According to company guidance, Hassabis has stated that the funding supports Isomorphic's ambition to build a scalable drug design engine capable of addressing diseases across multiple therapeutic domains. The capital will be deployed to refine and expand the IsoDDE platform, scale global operations, and advance Isomorphic's internal drug development pipeline toward clinical trial entry. The company is simultaneously working with established pharmaceutical partners including Eli Lilly and Novartis, indicating both internal development and partnership-based commercialization strategies.
The funding composition—heavily weighted toward Alphabet-affiliated entities alongside tier-one sovereign wealth funds and government backing—reflects institutional recognition that AI-driven drug discovery has matured beyond speculative territory. The participation of Temasek and MGX, alongside the U.K. sovereign AI fund, signals geopolitical competition for AI biotech leadership. For institutional investors, the round signals Alphabet's deepening commitment to biotech as a core growth vector and validates the venture-scale capital requirements now needed to compete in AI-native therapeutics discovery.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.